From Novartis on April 20, 2023

• The ALITHIOS open-label extension study demonstrated that continuous treatment with Kesimpta® (ofatumumab) for up to five years in relapsing multiple sclerosis (RMS) was associated with reduced risk of disability progression versus those who switched later from teriflunomide to Kesimpta.
• Outcomes related to both disability progression and brain volume change up to five years favored earlier initiation of Kesimpta in people living with RMS.
• A separate ALITHIOS analysis showed consistent safety profile of Kesimpta treatment for up to five years in people with RMS and in . . .
  
  This content is for paid subscribers.
  Please click here to subscribe or here to log in.
  Today’s Highlights

  Novartis (NVS)

  April 20, 2023
  Tweet Pin It